Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 8/20 | 0.57 |
| ▸ | PNP | P00491 | 4/20 | 0.55 |
| ▸ | TK1 | P04183 | 2/20 | 0.54 |
| ▸ | BLM | P54132 | 2/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | EDNRA | P25101 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | HBB | P68871 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | VCP | P55072 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL986800 | 0.82 | XDH (0.60) | XDHPNPTK1BLMUSP2 | |
| SCHEMBL41787 | 0.81 | XDH (0.59) | XDHPNPTK1BLMUSP2 | |
| SCHEMBL15005119 | 0.81 | XDH (0.59) | XDHPNPTK1BLMUSP2 | |
| SCHEMBL27667185 | 0.81 | XDH (0.63) | XDHPNPTK1BLMUSP2 | |
| SCHEMBL23679502 | 0.79 | HPGD (0.46) | XDHPNPTK1BLMUSP2 | |
| SCHEMBL1843776 | 0.79 | XDH (0.57) | XDHPNPTK1BLMUSP2 | |
| SCHEMBL22533906 | 0.79 | XDH (0.57) | XDHPNPTK1BLMUSP2 | |
| SCHEMBL21362203 | 0.79 | XDH (0.41) | XDHPNPTK1BLMUSP2 | |
| SCHEMBL8886034 | 0.79 | XDH (0.58) | XDHPNPTK1BLMUSP2 | |
| 9-Methylguanine SCHEMBL22884 | 0.79 | XDH (0.58) | XDHPNPTK1BLMUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4234566-A1 | MODIFIED NUCLEOSIDE OR NUCLEOTIDE | BGI Shenzhen (CN) | 2023-08-30 | — | — | EP | disclosed |
| EP-4219516-A2 | CHIRAL CONTROL | Wave Life Sciences Ltd. (SG) | 2023-08-02 | — | — | EP | disclosed |
| US-20230135545-A1 | BIOMIMETIC G-QUARTET COMPOUNDS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2023-05-04 | — | — | US | disclosed |
| WO-2023280156-A1 | MODIFIED NUCLEOSIDE OR NUCLEOTIDE | 深圳华大生命科学研究院 | 2023-01-12 | — | — | WO | disclosed |
| EP-2872147-B1 | METHOD FOR MAKING CHIRAL OLIGONUCLEOTIDES | WAVE LIFE SCIENCES LTD (SG) | 2022-12-21 | — | — | EP | disclosed |
| EP-3765474-B1 | CYCLOPENTANE-BASED MODULATORS OF STING (STIMULATOR OF INTERFERON GENES) | PFIZER (US) | 2022-06-15 | — | — | EP | disclosed |
| WO-2022083686-A1 | MODIFIED NUCLEOSIDE OR NUCLEOTIDE | 深圳华大生命科学研究院 | 2022-04-28 | — | — | WO | disclosed |
| US-10730904-B2 | Method for liquid-phase synthesis of nucleic acid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-08-04 | — | — | US | disclosed |
| EP-3401320-B1 | ACYCLIC NUCLEOSIDE PHOSPHONATE DIESTERS FOR USE IN TREATING HUMAN PAPILLOMA VIRUS, CERVICAL INTRAEPITHELIAL NEOPLASIA, ANAL INTRAEPITHELIAL NEOPLASIA, OR VULVAR INTRAEPITHELIAL NEOPLASIA | UNIV CALIFORNIA (US) | 2020-05-13 | — | — | EP | disclosed |
| WO-2019175776-A1 | CYCLOPENTANE-BASED MODULATORS OF STING (STIMULATOR OF INTERFERON GENES) | PFIZER INC. (US) | 2019-09-19 | — | — | WO | disclosed |
| US-7034152-B2 | Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta )]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-04-25 | — | — | US | disclosed |
| EP-1644384-A2 | PROCESS AND INTERMEDIATES FOR SYNTHESIS ENTECAVIR | Bristol-Myers Squibb Company (US) | 2006-04-12 | — | — | EP | disclosed |
| EP-1414822-B1 | IMPROVED SYNTHESIS OF BRANCHED ACYCLIC NUCLEOSIDES | MEDIVIR AB (SE) | 2005-02-16 | — | — | EP | disclosed |
| CN-1547582-A | Synthesis of branched acyclic nucleosides | ά | 2004-11-17 | — | — | CN | disclosed |
| US-20040192912-A1 | Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-30 | — | — | US | disclosed |
| US-20040147743-A1 | Synthesis of branched acyclic nucleosides | BANK OF NEW YORK, THE | 2004-07-29 | — | — | US | disclosed |
| WO-2004052310-A2 | PROCESS AND INTERMEDIATES FOR SYNTHESIS ENTECAVIR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-06-24 | — | — | WO | disclosed |
| EP-1414822-A1 | IMPROVED SYNTHESIS OF BRANCHED ACYCLIC NUCLEOSIDES | MEDIVIR AB (SE) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003002564-A1 | IMPROVED SYNTHESIS OF BRANCHED ACYCLIC NUCLEOSIDES | MEDIVIR AB (SE) | 2003-01-09 | — | — | WO | disclosed |
| WO-1999030561-A1 | NUCLEOTIDE-BASED PRODRUGS | NEXSTAR PHARMACEUTICALS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192912-A1 | Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | SAMHD1, NUDT1, ENTPD1 | XDH 1461/4885PNP 19/4885TK1 329/4885 |
| US-20230135545-A1 | BIOMIMETIC G-QUARTET COMPOUNDS | PYM1, B4GALT1, NGLY1 | XDH 445/4885PNP 3663/4885TK1 2219/4885 |
| US-10730904-B2 | Method for liquid-phase synthesis of nucleic acid | RNGTT, POLR2H, POLR2E | XDH 580/4885PNP 266/4885TK1 104/4885 |
| US-20040147743-A1 | Synthesis of branched acyclic nucleosides | SI, POLL, ME1 | XDH 287/4885PNP 17/4885TK1 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.